Paula B Blomquist

Datos Biográficos

ID10726352
NOMBREPaula B Blomquist
NOMBRESPaula B
APELLIDOBlomquist
FIRMABLOMQUIST P B
AFILIACIONESFrom the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un
VERIFICADONo
TOTAL DE OBRAS1
TOTAL DE CITAS0
TOTAL COMO AUTOR1
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2022
AÑO MÁS RECIENTE DE PUBLICACIÓN2022
ÍNDICE H0

  • Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

    Nick Andrews, Julia Stowe et al.ARTICLENew England Journal of Medicine2022

    BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case-control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine…